JP2014530861A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530861A5 JP2014530861A5 JP2014537216A JP2014537216A JP2014530861A5 JP 2014530861 A5 JP2014530861 A5 JP 2014530861A5 JP 2014537216 A JP2014537216 A JP 2014537216A JP 2014537216 A JP2014537216 A JP 2014537216A JP 2014530861 A5 JP2014530861 A5 JP 2014530861A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- kinase inhibitor
- tor kinase
- use according
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 11
- 229920003245 polyoctenamer Polymers 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 201000009251 multiple myeloma Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 4
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000005017 Glioblastoma Diseases 0.000 claims 2
- 101710042656 BQ2027_MB1231C Proteins 0.000 claims 1
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 210000003372 Endocrine Glands Anatomy 0.000 claims 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 1
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 201000010915 glioblastoma multiforme Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000001394 metastastic Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims 1
Claims (14)
- 固形腫瘍、非ホジキンリンパ腫または多発性骨髄腫を処置するための薬学的組成物の製造における、有効量のＴＯＲキナーゼ阻害剤の使用であって、
上記ＴＯＲキナーゼ阻害剤は、式（Ｉ）、式（Ｉａ）、式（Ｉｂ）、式（Ｉｃ）、式（Ｉｄ）、式（Ｉｅ）、式（Ｉｆ）、式（Ｉｇ）、式（ＩＩ）、式（ＩＩａ）、式（ＩＩｂ）、式（ＩＩｃ）、式（ＩＩｄ）、式（ＩＩＩ）または式（ＩＶ）によって表される、使用。 - 上記固形腫瘍は悪化した固形腫瘍である、請求項１に記載の使用。
- 上記固形腫瘍は神経内分泌腫瘍である、請求項１に記載の使用。
- 上記神経内分泌腫瘍は、腸原発性、非膵臓原発性または原発未知である、請求項３に記載の使用。
- 上記神経内分泌腫瘍は、症候性の内分泌腺生成腫瘍または非機能的な腫瘍である、請求項３に記載の使用。
- 上記神経内分泌腫瘍は、局部的に切除不能であるか、中程度に転移性であるか、高分化しているか、低い（グレード１）か、または中程度（グレード２）である、請求項３に記載の使用。
- 上記固形腫瘍は、非小細胞肺がん、多型性グリア芽腫、肝細胞がん、乳がん、結腸直腸がん、唾液腺がん、膵臓がん、腺様嚢胞がんまたは副腎がんである、請求項１に記載の使用。
- 上記乳がんは、ＥＲ＋／Ｈｅｒ２−、ＥＲ＋／Ｈｅｒ＋、ＥＲ−／Ｈｅｒ２＋、またはトリプルネガティブである、請求項７に記載の使用。
- 上記非ホジキンリンパ腫は、びまん性大細胞Ｂ細胞型リンパ腫である、請求項１に記載の使用。
- Response Evaluation Criteria in Solid Tumors（RECIST 1.1）によって決定されているような完全奏効、部分奏効または安定を、固定腫瘍を有している患者において実現するための薬学的組成物の製造における、有効量のＴＯＲキナーゼ阻害剤の使用であって、
上記ＴＯＲキナーゼ阻害剤は、式（Ｉ）、式（Ｉａ）、式（Ｉｂ）、式（Ｉｃ）、式（Ｉｄ）、式（Ｉｅ）、式（Ｉｆ）、式（Ｉｇ）、式（ＩＩ）、式（ＩＩａ）、式（ＩＩｂ）、式（ＩＩｃ）、式（ＩＩｄ）、式（ＩＩＩ）または式（ＩＶ）によって表される、使用。 - 非ホジキンリンパ腫についてのInternational Workshop Criteria（IWC）によって決定されているような完全寛解、部分寛解または安定を、非ホジキンリンパ腫を有している患者において実現するための薬学的組成物の製造における、有効量のＴＯＲキナーゼ阻害剤の使用であって、
上記ＴＯＲキナーゼ阻害剤は、式（Ｉ）、式（Ｉａ）、式（Ｉｂ）、式（Ｉｃ）、式（Ｉｄ）、式（Ｉｅ）、式（Ｉｆ）、式（Ｉｇ）、式（ＩＩ）、式（ＩＩａ）、式（ＩＩｂ）、式（ＩＩｃ）、式（ＩＩｄ）、式（ＩＩＩ）または式（ＩＶ）によって表される、使用。 - 多発性骨髄腫についてのInternational Uniform Response Criteria for Multiple Myeloma（IURC）によって決定されているような厳密な完全奏効、完全奏効、または非常に良好な部分奏効を、多発性骨髄腫を有している患者において実現するための薬学的組成物の製造における、有効量のＴＯＲキナーゼ阻害剤の使用であって、
上記ＴＯＲキナーゼ阻害剤は、式（Ｉ）、式（Ｉａ）、式（Ｉｂ）、式（Ｉｃ）、式（Ｉｄ）、式（Ｉｅ）、式（Ｉｆ）、式（Ｉｇ）、式（ＩＩ）、式（ＩＩａ）、式（ＩＩｂ）、式（ＩＩｃ）、式（ＩＩｄ）、式（ＩＩＩ）または式（ＩＶ）によって表される、使用。 - Eastern Cooperative Oncology Group Performance Status（ECOG）の全身状態または多型性グリア芽腫のためのResponse Assessment for Neuro-Oncology（RANO）ワーキンググループにとっての反応評価を、非ホジキンリンパ腫、多発性骨髄腫または多型性グリア芽腫を有している患者において改善するための薬学的組成物の製造における、有効量のＴＯＲキナーゼ阻害剤の使用であって、
上記ＴＯＲキナーゼ阻害剤は、式（Ｉ）、式（Ｉａ）、式（Ｉｂ）、式（Ｉｃ）、式（Ｉｄ）、式（Ｉｅ）、式（Ｉｆ）、式（Ｉｇ）、式（ＩＩ）、式（ＩＩａ）、式（ＩＩｂ）、式（ＩＩｃ）、式（ＩＩｄ）、式（ＩＩＩ）または式（ＩＶ）によって表される、使用。 - 上記ＴＯＲキナーゼ阻害剤は、表Ａ、Ｂ、ＣまたはＤの化合物である、請求項１〜１３のいずれか１項に記載の使用。
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549034P | 2011-10-19 | 2011-10-19 | |
| US61/549,034 | 2011-10-19 | ||
| US201261591401P | 2012-01-27 | 2012-01-27 | |
| US61/591,401 | 2012-01-27 | ||
| US201261647233P | 2012-05-15 | 2012-05-15 | |
| US61/647,233 | 2012-05-15 | ||
| US201261653436P | 2012-05-31 | 2012-05-31 | |
| US61/653,436 | 2012-05-31 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016234951A Division JP6360136B2 (ja) | 2011-10-19 | 2016-12-02 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014530861A JP2014530861A (ja) | 2014-11-20 |
| JP2014530861A5 true JP2014530861A5 (ja) | 2015-11-12 |
Family
ID=47116477
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537216A Pending JP2014530861A (ja) | 2011-10-19 | 2012-10-18 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2016234951A Active JP6360136B2 (ja) | 2011-10-19 | 2016-12-02 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2018117932A Pending JP2018162286A (ja) | 2011-10-19 | 2018-06-21 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2020117028A Pending JP2020169203A (ja) | 2011-10-19 | 2020-07-07 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2021078559A Pending JP2021107461A (ja) | 2011-10-19 | 2021-05-06 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016234951A Active JP6360136B2 (ja) | 2011-10-19 | 2016-12-02 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2018117932A Pending JP2018162286A (ja) | 2011-10-19 | 2018-06-21 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2020117028A Pending JP2020169203A (ja) | 2011-10-19 | 2020-07-07 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2021078559A Pending JP2021107461A (ja) | 2011-10-19 | 2021-05-06 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9493466B2 (ja) |
| EP (3) | EP3466423B1 (ja) |
| JP (5) | JP2014530861A (ja) |
| KR (1) | KR101978537B1 (ja) |
| CN (2) | CN103998036B (ja) |
| BR (1) | BR112014009755B1 (ja) |
| CA (1) | CA2852921C (ja) |
| EA (2) | EA030664B1 (ja) |
| ES (2) | ES2894958T3 (ja) |
| HK (1) | HK1243919A1 (ja) |
| IL (3) | IL232128B (ja) |
| IN (1) | IN2014CN02887A (ja) |
| MX (3) | MX348566B (ja) |
| MY (1) | MY183661A (ja) |
| SG (3) | SG10201505102WA (ja) |
| TW (4) | TWI758746B (ja) |
| UA (1) | UA115319C2 (ja) |
| WO (1) | WO2013059396A2 (ja) |
| ZA (2) | ZA201402771B (ja) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| NZ630467A (en) | 2013-01-16 | 2017-02-24 | Signal Pharm Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| EP2961408A1 (en) * | 2013-02-28 | 2016-01-06 | Signal Pharmaceuticals, LLC | Treatment of cancer with tor kinase inhibitors |
| CA2908957C (en) | 2013-04-17 | 2021-05-18 | Signal Pharmaceuticals, Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| MX2015014596A (es) * | 2013-04-17 | 2016-03-03 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer. |
| MX368286B (es) * | 2013-04-17 | 2019-09-27 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. |
| EP2986319A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer |
| EP4218763A1 (en) * | 2013-04-17 | 2023-08-02 | Signal Pharmaceuticals, LLC | 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one for treating glioblastoma multiforme |
| WO2014172423A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| TWI631949B (zh) * | 2013-04-17 | 2018-08-11 | 標誌製藥公司 | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| WO2014172426A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| CN107474051B (zh) * | 2013-05-29 | 2020-10-30 | 西格诺药品有限公司 | 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途 |
| MX2016004212A (es) * | 2013-10-04 | 2016-07-11 | Signal Pharm Llc | Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas. |
| US9737535B2 (en) | 2014-04-16 | 2017-08-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines |
| EP3131551A4 (en) | 2014-04-16 | 2017-09-20 | Signal Pharmaceuticals, LLC | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| WO2015160882A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| CA2955009A1 (en) | 2014-07-14 | 2016-01-21 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| CN114702495A (zh) * | 2015-11-20 | 2022-07-05 | 福马治疗有限公司 | 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮 |
| US10765681B2 (en) | 2016-02-05 | 2020-09-08 | Academia Sinica | Purine compounds possessing anticancer activity |
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
| EA037745B1 (ru) | 2016-12-20 | 2021-05-18 | Астразенека Аб | Аминотриазолопиридиновые соединения и их применение в лечении рака |
| BR112019027402A2 (pt) | 2017-06-22 | 2020-07-07 | Celgene Corporation | tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b |
| SG11202003657VA (en) * | 2017-11-01 | 2020-05-28 | Juno Therapeutics Inc | Process for producing a t cell composition |
| CN111902413B (zh) | 2018-03-09 | 2023-10-17 | 里科瑞尔姆Ip控股有限责任公司 | 取代的1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮 |
| CN110526907B (zh) * | 2018-05-23 | 2021-04-23 | 四川大学 | 苯并噁嗪酮类衍生物及其应用 |
| JP2022542396A (ja) * | 2019-07-31 | 2022-10-03 | ライボン・セラピューティクス・インコーポレイテッド | Ｃｄ３８の阻害剤としてのヘテロ二環式アミド |
| TWI768550B (zh) * | 2019-11-22 | 2022-06-21 | 大陸商南京明德新藥研發有限公司 | 作為dna-pk抑制劑的嘧啶并吡咯類螺環化合物及其衍生物 |
| AU2020390962B2 (en) * | 2019-11-25 | 2023-09-28 | Zai Lab (Shanghai) Co., Ltd | Pyrimidoimidazole compounds used as DNA-PK inhibitors |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE262026C (ja) | ||||
| US3507866A (en) | 1967-08-08 | 1970-04-21 | Merck & Co Inc | 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation |
| US3567725A (en) | 1968-11-20 | 1971-03-02 | Merck & Co Inc | Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones |
| US4317909A (en) | 1980-03-24 | 1982-03-02 | Sterling Drug Inc. | Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones |
| US4294837A (en) | 1980-03-28 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use |
| US4294836A (en) | 1980-03-24 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use |
| US4309537A (en) | 1980-03-28 | 1982-01-05 | Sterling Drug Inc. | Production of imidazo[4,5-b]pyridin-2-ones or thiones |
| GB8709448D0 (en) | 1987-04-21 | 1987-05-28 | Pfizer Ltd | Heterobicyclic quinoline derivatives |
| JPS63275582A (ja) | 1987-05-02 | 1988-11-14 | Naade Kenkyusho:Kk | ２−アミノイミダゾ〔４，５−ｂ〕ピリジン誘導体の製造方法 |
| DD262026A1 (de) | 1987-07-10 | 1988-11-16 | Akad Wissenschaften Ddr | Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen |
| FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
| US4963561A (en) | 1990-02-28 | 1990-10-16 | Sterling Drug Inc. | Imidazopyridines, their preparation and use |
| TW274550B (ja) | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
| DE19601627A1 (de) | 1996-01-18 | 1997-07-24 | Bayer Ag | Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone |
| US6031105A (en) | 1996-04-09 | 2000-02-29 | Pfizer Inc | Substituted pyridines |
| DK1017384T3 (da) | 1997-09-26 | 2005-01-31 | Zentaris Gmbh | Azabenzimidazolbaserede forbindelser til modulation af serin/threoninproteinkinasefunktion |
| ZA9810490B (en) | 1997-12-03 | 1999-05-20 | Dainippon Pharmaceutical Co | 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor |
| JP2003146987A (ja) | 1999-05-31 | 2003-05-21 | Dainippon Pharmaceut Co Ltd | ２−アリールプリン−９−アセトアミド誘導体 |
| JP3814125B2 (ja) | 1999-06-02 | 2006-08-23 | 大日本住友製薬株式会社 | ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬 |
| JP2002100363A (ja) | 2000-09-25 | 2002-04-05 | Mitsubishi Chemicals Corp | リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池 |
| JP2002167387A (ja) | 2000-11-29 | 2002-06-11 | Dainippon Pharmaceut Co Ltd | ２−（７，８−ジヒドロ−８−オキソ−９ｈ−プリン−９−イル）酢酸誘導体 |
| WO2002048152A2 (en) | 2000-12-12 | 2002-06-20 | Neurogen Corporation | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines |
| WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| HUP0401293A3 (en) | 2001-09-04 | 2008-03-28 | Boehringer Ingelheim Pharma | Novel dihydropteridinones, method for producing the same and the use thereof as medicaments |
| US6825184B2 (en) | 2001-10-18 | 2004-11-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-Disubstituted benzo-fused urea compounds |
| US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
| EP1501850A2 (en) | 2002-05-06 | 2005-02-02 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
| WO2004042002A2 (en) | 2002-08-05 | 2004-05-21 | University Of Massachusetts | Compounds for modulating rna interference |
| EP1556053A4 (en) | 2002-10-31 | 2006-04-19 | Amgen Inc | ANTI-INFLAMMATORY AGENTS |
| MXPA05007503A (es) | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
| EA008778B1 (ru) | 2003-02-26 | 2007-08-31 | Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Дигидроптеридиноны, способ их получения и их применение в качестве лекарственных средств |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| EP1615669A2 (en) | 2003-04-23 | 2006-01-18 | Wyeth Holdings Corporation | Peg-wortmannin conjugates |
| US7429572B2 (en) | 2003-05-30 | 2008-09-30 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| JP4705912B2 (ja) | 2003-06-26 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | ベンゾジアゼピンｃｇｒｐ受容体拮抗物質 |
| WO2005120511A1 (en) | 2004-06-04 | 2005-12-22 | Icos Corporation | Methods for treating mast cell disorders |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| WO2006001266A1 (ja) | 2004-06-23 | 2006-01-05 | Banyu Pharmaceutical Co., Ltd. | ２－アリールプリン誘導体の製造方法 |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| WO2006036883A2 (en) | 2004-09-24 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Imidazo{4,5-b}pyrazinone inhibitors of protein kinases |
| US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| CN101048410B (zh) | 2004-10-29 | 2010-06-23 | 泰博特克药品有限公司 | 抑制hiv的双环嘧啶衍生物 |
| SE0403006D0 (sv) | 2004-12-09 | 2004-12-09 | Biovitrum Ab | New compounds |
| AU2005316668B2 (en) | 2004-12-13 | 2012-09-06 | Millennium Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
| DK1853588T3 (da) | 2005-02-16 | 2008-09-15 | Astrazeneca Ab | Kemiske forbindelser |
| WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
| EP1874772A1 (en) | 2005-04-05 | 2008-01-09 | Pharmacopeia, Inc. | Purine and imidazopyridine derivatives for immunosuppression |
| DK2275103T3 (da) | 2005-11-21 | 2014-07-07 | Novartis Ag | mTor-inhibitorer ved behandling af endokrine tumorer |
| US20090281075A1 (en) | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
| ES2558517T3 (es) * | 2006-08-02 | 2016-02-04 | Cytokinetics, Inc. | Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas |
| US20100144738A1 (en) | 2006-09-05 | 2010-06-10 | William Bornmann | Inhibitors of c-met and uses thereof |
| EP2063882A4 (en) | 2006-09-05 | 2010-03-03 | Univ Emory | TYROSINKINASE INHIBITOR FOR PREVENTING OR TREATING INFECTIONS |
| US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US7919490B2 (en) | 2006-10-04 | 2011-04-05 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| ES2631003T3 (es) * | 2006-10-19 | 2017-08-25 | Signal Pharmaceuticals, Llc | Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos |
| CA2666624C (en) | 2006-10-19 | 2015-12-29 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
| EP2219646A4 (en) | 2007-12-21 | 2010-12-22 | Univ Rochester | METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS |
| US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| AU2009314631B2 (en) * | 2008-11-12 | 2014-07-31 | Takeda Pharmaceutical Company Limited | Pyrazinopyrazines and derivatives as kinase inhibitors |
| ES2554375T3 (es) * | 2008-11-25 | 2015-12-18 | University Of Rochester | Inhibidores de las MLK y métodos de uso |
| EP2493472B1 (en) * | 2009-10-26 | 2016-12-07 | Signal Pharmaceuticals, LLC | Methods of synthesis and purification of heteroaryl compounds |
| UA110697C2 (uk) * | 2010-02-03 | 2016-02-10 | Сігнал Фармасьютікалз, Елелсі | ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK |
| US20120028972A1 (en) * | 2010-07-30 | 2012-02-02 | Lilly Wong | Biomarker assays for detecting or measuring inhibition of tor kinase activity |
| WO2013019927A1 (en) | 2011-08-03 | 2013-02-07 | Signal Pharmaceuticals, Llc | Identification of gene expression profile as a predictive biomarker for lkb1 status |
| MY169749A (en) | 2011-12-02 | 2019-05-15 | Signal Pharm Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
-
2012
- 2012-10-18 MY MYPI2017000252A patent/MY183661A/en unknown
- 2012-10-18 KR KR1020147012908A patent/KR101978537B1/ko active IP Right Grant
- 2012-10-18 CN CN201280062920.5A patent/CN103998036B/zh active Active
- 2012-10-18 TW TW109119519A patent/TWI758746B/zh active
- 2012-10-18 UA UAA201405225A patent/UA115319C2/uk unknown
- 2012-10-18 EP EP18207204.1A patent/EP3466423B1/en active Active
- 2012-10-18 JP JP2014537216A patent/JP2014530861A/ja active Pending
- 2012-10-18 MX MX2014004775A patent/MX348566B/es active IP Right Grant
- 2012-10-18 MX MX2017002007A patent/MX357833B/es unknown
- 2012-10-18 CN CN201710320646.1A patent/CN107157990B/zh active Active
- 2012-10-18 SG SG10201505102WA patent/SG10201505102WA/en unknown
- 2012-10-18 EA EA201490814A patent/EA030664B1/ru not_active IP Right Cessation
- 2012-10-18 TW TW106118909A patent/TWI713752B/zh active
- 2012-10-18 WO PCT/US2012/060723 patent/WO2013059396A2/en active Application Filing
- 2012-10-18 SG SG10201912850WA patent/SG10201912850WA/en unknown
- 2012-10-18 BR BR112014009755-0A patent/BR112014009755B1/pt active IP Right Grant
- 2012-10-18 EP EP12780374.0A patent/EP2768500B1/en active Active
- 2012-10-18 CA CA2852921A patent/CA2852921C/en active Active
- 2012-10-18 US US13/654,441 patent/US9493466B2/en active Active
- 2012-10-18 MX MX2020004689A patent/MX2020004689A/es unknown
- 2012-10-18 ES ES18207204T patent/ES2894958T3/es active Active
- 2012-10-18 ES ES12780374T patent/ES2751921T3/es active Active
- 2012-10-18 IN IN2887CHN2014 patent/IN2014CN02887A/en unknown
- 2012-10-18 EA EA201890768A patent/EA034512B1/ru not_active IP Right Cessation
- 2012-10-18 SG SG11201401630SA patent/SG11201401630SA/en unknown
- 2012-10-18 TW TW106118908A patent/TWI708605B/zh active
- 2012-10-18 EP EP20152170.5A patent/EP3659599B1/en active Active
- 2012-10-18 TW TW101138515A patent/TWI629983B/zh active
-
2014
- 2014-04-13 IL IL232128A patent/IL232128B/en active IP Right Grant
- 2014-04-15 ZA ZA2014/02771A patent/ZA201402771B/en unknown
- 2014-10-24 ZA ZA2014/07793A patent/ZA201407793B/en unknown
-
2016
- 2016-09-27 US US15/277,285 patent/US9937170B2/en active Active
- 2016-12-02 JP JP2016234951A patent/JP6360136B2/ja active Active
-
2018
- 2018-01-10 IL IL256828A patent/IL256828B/en active IP Right Grant
- 2018-02-20 US US15/899,706 patent/US11166950B2/en active Active
- 2018-03-09 HK HK18103366.0A patent/HK1243919A1/zh unknown
- 2018-06-21 JP JP2018117932A patent/JP2018162286A/ja active Pending
-
2020
- 2020-07-07 JP JP2020117028A patent/JP2020169203A/ja active Pending
-
2021
- 2021-03-01 IL IL281180A patent/IL281180B2/en unknown
- 2021-05-06 JP JP2021078559A patent/JP2021107461A/ja active Pending
- 2021-10-07 US US17/496,433 patent/US20220273650A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530861A5 (ja) | ||
| JP2010501572A5 (ja) | ||
| WO2012016133A3 (en) | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers | |
| JP2017528475A5 (ja) | ||
| WO2012061557A3 (en) | Chemical compounds | |
| JP2013508417A5 (ja) | ||
| MX2011007420A (es) | Compuestos, composiciones y metodos para prevenir la metastasis de las celulas cancerigenas. | |
| NZ706999A (en) | Inhibitors of mutant isocitrate dehydrogenase and therapeutical uses thereof | |
| WO2013093508A3 (en) | Wnt pathway inhibitors | |
| BR112012015745A2 (pt) | compostos e métodos para a modulação de quinase, e indicações dos mesmos | |
| RU2018145048A (ru) | Способы и композиции для лечения злокачественных опухолей, резистентных к ингибиторам пути non-erk марк | |
| CR20150368A (es) | Inhibidores de histona desmetilasa | |
| EA201791585A1 (ru) | Способ и композиции для ингибирования миграции клеток опухоли и образования метастазов | |
| WO2014152389A8 (en) | Imaging agent for detection of diseased cells | |
| HRP20131081T1 (hr) | Kombinirane terapije koje sadrže hinoksalin inhibitor p13k-alfa za uporabu u lijeäśenju kancera | |
| MY156210A (en) | Compounds and methods for kinase modulation, and indications therefor | |
| JP2013512263A5 (ja) | ||
| MX370662B (es) | Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer. | |
| WO2014165782A3 (en) | Compositions, methods, and kits comprising platinum compounds associated with a ligand comprising a targeting moiety | |
| EA201490472A1 (ru) | Комбинированная терапия рака hsp90-ингибитором и антиметаболитом | |
| PE20170384A1 (es) | Compuesto piridinicos de planieolida y metodos de uso | |
| IN2014DN07283A (ja) | ||
| WO2014130410A8 (en) | Dppf-like compounds and methods | |
| EA201492004A1 (ru) | Органические композиции для лечения kras-ассоциированных заболеваний | |
| MX2014003376A (es) | Derivados de acido benzoico como inhibidores eif4e. |